PreveCeutical Medical Inc.

Head quartered in Vancouver, British Columbia, PreveCeutical Medical Inc. has a world class team with a passion for researching and developing innovative solutions for unmet clinical needs. Bringing to market treatments and therapies that make real, palpable differences in the lives of those who need them. The company is staking out important positions in diverse areas such as diabetes and obesity, pain management, neurological disorders and cancer.

Our Story

2009 - 2014
Stephen Van Deventer, a seasoned business person and venture capitalist and Kimberly Van Deventer, a successful entrepreneur met in 2009 and formed a business partnership. This was a great meeting of minds. In 2010 they started Cornerstone Global Partners, a venture capital, and business development company. They were involved in a number of ventures and building companies.

2015 - 2016
Steve and Kimberly were very interested in the health and wellness market. They started looking into the utilisation of nature and science for the benefit of health-conscious consumers. With that in mind, they coined and trademarked the word PreveCeutical to which captures the demand for preventive health products and nutraceuticals. They formed PreveCeutical Medical Inc., a company that was incorporated in British Columbia on October 2nd, 2015. They were introduced to a therapy which included a polarized scorpion venom treatment which was developed by Dr. Arthur Mikaelian. PreveCeutical entered into an agreement for the exclusive worldwide right to manufacture and distribute the blue scorpion venom product under the trade name CELLB9®, which is being marketed and sold by PreveCeutical.

Steve and Kimberly raised equity with the help of friends, family and associates which provided the capital to grow the company including creating a team that works with them to further the business purpose. They continued to look for innovative solutions and products that promote good health and wellness.

2017
With a continued focus on utilising nature and science, in April 2017 PreveCeutical formed a partnership with UniQuest Pty Limited, the main commercialisation company for the University of Queensland in which UniQuest will conduct a number of research programs for PreveCeutical. Continued growth in the company has and is fostering amazing partnerships. In May of this year a partnership with Uniquest at the Queensland University was struck; Australia’s leading commercialisation entity consistently in the top tier of technology transfer worldwide. With development programs for four exciting therapies underway, PreveCeutical is moving steadily forward. The team is celebrating the success of their IPO in their new corporate office space.